FDA Brief

Warning letters Drugs

FDA warning letter to

Cosco International, Inc.

High riskIssued Apr 14, 2025Posted Apr 29, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Cosco International over nonprescription drug manufacturing failures and unapproved drug products.

What happened

FDA inspected Cosco International’s Marietta, Georgia drug manufacturing facility from October 15 to 25, 2024. The agency found inadequate process and cleaning validation, insufficient stability data, inadequate testing of water used in drug products, and quality-unit oversight failures. FDA also reviewed product labeling and found Carpe Antiperspirant Foot and Hand Lotions and a redacted skin protectant were unapproved new drugs and misbranded (illegally labeled); the company had not responded to the inspection observations FDA cited on its Form FDA 483 (inspection findings form).

What FDA found

  1. Failed to validate manufacturing processes for OTC drugs, including children’s wound gel and ear flush, before commercial distribution.

    21 CFR 211.100(a)
  2. Failed to validate cleaning of shared equipment used for drugs and cosmetics, so cross-contamination was not ruled out.

    21 CFR 211.100(a)
  3. Lacked adequate stability data to show drug products, including children’s wound products, met specifications through their labeled shelf-life.

    21 CFR 211.166(a)
  4. Failed to adequately test and validate testing of water used as a drug ingredient for bacteria, fungi, and objectionable organisms, and used a nonrepresentative sampling point.

    21 CFR 211.160(b)
  5. Quality control unit did not adequately oversee the stability program, expired raw-material controls, and computerized record access.

    21 CFR 211.22
  6. Marketed unapproved new drugs and misbranded (illegally labeled) products because the skin protectant combined active ingredients not allowed by OTC monograph M016 and the Carpe products claimed hand and foot use not allowed by M019.

    FD&C Act §§505(a), 301(d), 502(ee), 505G; 21 U.S.C. 355(a), 331(d), 352(ee), 355h

What FDA wants

FDA tells Cosco to correct the violations promptly and respond in writing within 15 working days with the actions taken and steps to prevent recurrence. If corrections cannot be completed in that time, the firm must state why and give a completion schedule; FDA also recommends a qualified current good manufacturing practice (CGMP) consultant and a six-system audit.

Who should pay attention

  • brands whose OTC drugs are made by Cosco
  • sellers of Carpe antiperspirant products
  • makers of children’s OTC wound-care drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk